Tuberculosis Cases Increase: Colloidal Silver to the Rescue!

Hi, Steve Barwick here, for The Silver Edge

An article in the Washington Post dated March 24, 2016 says tuberculosis (TB) cases have increased in the U.S. for the first time in 23 years.

With a total of 9,563 cases being reported in the U.S. in 2015, which is 157 cases over those reported the previous year, the Post claims medical experts aren't sure yet whether or not this increase could signal "a resurgence of one of the world's deadliest diseases."

The largest increases in cases of TB appear to be in California, Texas, Florida and New York – population centers constituting a whopping one-third of the U.S. population.

According to the Washington Post article:

"The disease is treatable with antibiotics, but the course can be long and complicated.

Certain forms of the bacterium that causes TB are becoming impervious to the drugs designed to kill them, leading to the development of multidrug-resistant strains of infection.

…In a related report, the CDC also called for increased awareness of the potential for active TB among foreign-born temporary workers."

Will Colloidal Silver Help?

Does colloidal silver work against TB?

Some experts say it will. Indeed, in one clinical study researchers concluded that silver nanoparticles, "showed excellent antibacterial activities against M. tuberculosis around 10 ppm."

The well-known and highly respected Dr. Gordon Pedersen wrote, in his 2014 book "A New Fighting Chance":

"Tuberculosis is a common and often deadly infectious disease caused by mycobacteria…silver has destroyed tuberculosis in laboratory studies.

By drinking two teaspoons twice daily and inhaling from a nebulizer 30 minutes each day, you may affect the tuberculosis in both the lungs and the bloodstream.

Tuberculosis is not easy to beat. This dosage may need to be followed for weeks or months. You should see benefits after the first dose and each repeated use."

According to a clinical study published in the Journal of Nanobiotechnology in May 2012, both gold and silver nanoparticles were demonstrated to be effective against the pathogen Bacillus Calmette-Guerin (BCG) which is used in clinical studies as a surrogate for the tuberculosis bacteria. The researchers wrote:

"Diseases such as tuberculosis (TB) have always had a large impact on human health. Bacillus Calmette-Guérin (BCG) is used as a surrogate for TB during the development of anti-TB drugs.

…The purpose of this study was to examine the potential of nanoparticles as anti-TB compounds by studying the interacting mechanisms between nanoparticles and bacteria.

Colloidal silver has been used as an antibacterial agent since ancient Greece. Unlike antibiotic drugs, bacteria cannot easily develop resistance because silver targets multiple components in the bacterial cell. As a result, silver is used in medical equipment coatings and dental resin components.

…In terms of anti-TB drug development, this study suggests that NPs may represent useful candidates, but will require significant development to ensure optimal bactericidal activity and low host toxicity."

– Journal of Nanobiotechnology, May 2012, "Antibacterial Activities of Gold and Silver Nanoparticles Against Escherichia coli and bacillus Calmette-Guerin

Of related interest, a company called Klearsen Corporation apparently at one point developed an inhalable lung treatment utilizing atomized particles of ionic silver along with a small amount of peppermint oil.

The treatment was designed for tuberculosis, as well as for Mycopbacterium Avium Complex (MAC), i.e., the cause of so-called "hot tub lung," in which the pathogens Mycobacterium avium or Mycobacterium abscessus infect the lungs similar to the way the tuberculosis pathogen does.

According to a Klearsen Corporation spokesman in March 2006, preliminary clinical studies had yielded some astonishing results:

"After having very good results against Mycobacterium tuberculosis, it seemed like the obvious step to screen the compound against M. avium and M. abscessus," said Steve Frank, the project director.

"We have been utilizing this compound in our patented Respiratory Inhalation Therapy treatment for years to deal with numerous ailments and this testing finally provides us with the substantiation necessary to move into the mycobacteria treatment arena."

Preliminary work with an MAC (Mycobacterium avium complex) patient in clinical trials has shown encouraging results and suggests that the treatment period for this condition could be reduced from a typical 12- to 16-month course of antibiotics to a 4-week course of the Klearsen Respiratory Inhalation Therapy.

'This is a very exciting period of demonstration for our KC-287 antimicrobial compound,' stated Chris Groutt, the Marketing Director. 'We have all seen the dramatic capabilities of this product and now it is finally reaching the surface where it can benefit huge portions of the population.'

The treatment utilizes a nebulized mist of KC-287 to repeatedly coat the inner surfaces of the lungs. Being on the air-side of the tissue and formulated to gain enhanced entry into the bacterial cells allow the active agent to very effectively kill the mycobacteria with very low total dose to the subject.

Although the treatment is still in the experimental stage, early results are so encouraging, that clinical studies are moving forward.

Paul Whittle, the CEO of Klearsen Corp., is anxious to see this technology applied to MAC as well as tuberculosis patients:

'Klearsen Corporation holds several patents relating to the respiratory therapy and the active agent. We are very pleased to see this level of performance in vivo.'"

While the above treatment was apparently patented by the Klearsen Corporation, and as of 2006 the company was "still seeking FDA approval." That approval was apparently never granted, and the company website no longer exists.

Nevertheless, people from around the world are reporting good effects after using colloidal silver for TB. As an example, according to an online health board, colloidal silver is being used by individuals in Nigeria to help stem the country's growing problem with tuberculosis. As one individual wrote:

"When we first started offering colloidal silver in 2007, we were approached by seven patients. Six were HIV positive and one had Tuberculosis. After three months of taking colloidal silver the lady with the TB was clean. Her doctor couldn't believe it."

Of course, anecdotal reports like that do not constitute "proof" that colloidal silver is effective against the TB pathogen. But you can learn more about silver's ability to kill the TB pathogen by reading the following two articles and related clinical study:


Steve Barwick
Steve Barwick

Author